FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005498096> ?p ?o ?g. }

• W2005498096 endingPage "20026" @default.
• W2005498096 startingPage "20021" @default.
• W2005498096 abstract "Restricting the cytotoxicity of anticancer agents by targeting receptors exclusively expressed on tumor cells is critical when treating infiltrative brain tumors such as glioblastoma multiforme (GBM). GBMs express an IL-13 receptor (IL13Rα2) that differs from the physiological IL4R/IL13R receptor. We developed a regulatable adenoviral vector (Ad.mhIL-4.TRE.mhIL-13-PE) encoding a mutated human IL-13 fused to Pseudomonas exotoxin (mhIL-13-PE) that specifically binds to IL13Rα2 to provide sustained expression, effective anti-GBM cytotoxicity, and minimal neurotoxicity. The therapeutic Ad also encodes mutated human IL-4 that binds to the physiological IL4R/IL13R without interacting with IL13Rα2, thus inhibiting potential binding of mhIL-13-PE to normal brain cells. Using intracranial GBM xenografts and syngeneic mouse models, we tested the Ad.mhIL-4.TRE.mhIL-13-PE and two protein formulations, hIL-13-PE used in clinical trials (Cintredekin Besudotox) and a second-generation mhIL-13-PE. Cintredekin Besudotox doubled median survival without eliciting long-term survival and caused severe neurotoxicity; mhIL-13-PE led to ∼40% long-term survival, eliciting severe neurological toxicity at the high dose tested. In contrast, Ad-mediated delivery of mhIL-13-PE led to tumor regression and long-term survival in over 70% of the animals, without causing apparent neurotoxicity. Although Cintredekin Besudotox was originally developed to target GBM, when tested in a phase III trial it failed to achieve clinical endpoints and revealed neurotoxicity. Limitations of Cintredekin Besudotox include its short half-life, which demanded frequent or continued administration, and binding to IL4R/IL13R, present in normal brain cells. These shortcomings were overcome by our therapeutic Ad, thus representing a significant advance in the development of targeted therapeutics for GBM." @default.
• W2005498096 created "2016-06-24" @default.
• W2005498096 creator A5015177135 @default.
• W2005498096 creator A5022723078 @default.
• W2005498096 creator A5028661050 @default.
• W2005498096 creator A5036408326 @default.
• W2005498096 creator A5037742354 @default.
• W2005498096 creator A5043155961 @default.
• W2005498096 creator A5049664474 @default.
• W2005498096 creator A5058075606 @default.
• W2005498096 creator A5067218028 @default.
• W2005498096 creator A5067686943 @default.
• W2005498096 creator A5073424560 @default.
• W2005498096 creator A5076105306 @default.
• W2005498096 creator A5078838422 @default.
• W2005498096 creator A5080277287 @default.
• W2005498096 creator A5081152738 @default.
• W2005498096 creator A5082380342 @default.
• W2005498096 creator A5084729731 @default.
• W2005498096 creator A5084738429 @default.
• W2005498096 date "2010-10-28" @default.
• W2005498096 modified "2023-09-26" @default.
• W2005498096 title "Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics" @default.
• W2005498096 cites W138433727 @default.
• W2005498096 cites W1963549136 @default.
• W2005498096 cites W1967044395 @default.
• W2005498096 cites W1982408495 @default.
• W2005498096 cites W1984553346 @default.
• W2005498096 cites W1986129213 @default.
• W2005498096 cites W1987045589 @default.
• W2005498096 cites W1988349499 @default.
• W2005498096 cites W1990408233 @default.
• W2005498096 cites W1995502373 @default.
• W2005498096 cites W1998360213 @default.
• W2005498096 cites W2002972290 @default.
• W2005498096 cites W2009063639 @default.
• W2005498096 cites W2045468193 @default.
• W2005498096 cites W2048043668 @default.
• W2005498096 cites W2056475500 @default.
• W2005498096 cites W2057962057 @default.
• W2005498096 cites W2068958639 @default.
• W2005498096 cites W2077476931 @default.
• W2005498096 cites W2077709559 @default.
• W2005498096 cites W2090407590 @default.
• W2005498096 cites W2096628715 @default.
• W2005498096 cites W2109839172 @default.
• W2005498096 cites W2116126240 @default.
• W2005498096 cites W2117058176 @default.
• W2005498096 cites W2132665714 @default.
• W2005498096 cites W2140621853 @default.
• W2005498096 cites W2147019056 @default.
• W2005498096 cites W2148276738 @default.
• W2005498096 cites W2158681922 @default.
• W2005498096 cites W2370823328 @default.
• W2005498096 cites W39922968 @default.
• W2005498096 doi "https://doi.org/10.1073/pnas.1008261107" @default.
• W2005498096 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2993419" @default.
• W2005498096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21030678" @default.
• W2005498096 hasPublicationYear "2010" @default.
• W2005498096 type Work @default.
• W2005498096 sameAs 2005498096 @default.
• W2005498096 citedByCount "82" @default.
• W2005498096 countsByYear W20054980962012 @default.
• W2005498096 countsByYear W20054980962013 @default.
• W2005498096 countsByYear W20054980962014 @default.
• W2005498096 countsByYear W20054980962015 @default.
• W2005498096 countsByYear W20054980962016 @default.
• W2005498096 countsByYear W20054980962017 @default.
• W2005498096 countsByYear W20054980962018 @default.
• W2005498096 countsByYear W20054980962019 @default.
• W2005498096 countsByYear W20054980962020 @default.
• W2005498096 countsByYear W20054980962021 @default.
• W2005498096 countsByYear W20054980962022 @default.
• W2005498096 countsByYear W20054980962023 @default.
• W2005498096 crossrefType "journal-article" @default.
• W2005498096 hasAuthorship W2005498096A5015177135 @default.
• W2005498096 hasAuthorship W2005498096A5022723078 @default.
• W2005498096 hasAuthorship W2005498096A5028661050 @default.
• W2005498096 hasAuthorship W2005498096A5036408326 @default.
• W2005498096 hasAuthorship W2005498096A5037742354 @default.
• W2005498096 hasAuthorship W2005498096A5043155961 @default.
• W2005498096 hasAuthorship W2005498096A5049664474 @default.
• W2005498096 hasAuthorship W2005498096A5058075606 @default.
• W2005498096 hasAuthorship W2005498096A5067218028 @default.
• W2005498096 hasAuthorship W2005498096A5067686943 @default.
• W2005498096 hasAuthorship W2005498096A5073424560 @default.
• W2005498096 hasAuthorship W2005498096A5076105306 @default.
• W2005498096 hasAuthorship W2005498096A5078838422 @default.
• W2005498096 hasAuthorship W2005498096A5080277287 @default.
• W2005498096 hasAuthorship W2005498096A5081152738 @default.
• W2005498096 hasAuthorship W2005498096A5082380342 @default.
• W2005498096 hasAuthorship W2005498096A5084729731 @default.
• W2005498096 hasAuthorship W2005498096A5084738429 @default.
• W2005498096 hasBestOaLocation W20054980962 @default.
• W2005498096 hasConcept C104317684 @default.
• W2005498096 hasConcept C109316439 @default.
• W2005498096 hasConcept C111599444 @default.
• W2005498096 hasConcept C126322002 @default.

• next